Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Natco Pharma gets...

    Natco Pharma gets green nod for Rs 480 crore expansion project

    Written by Ruby Khatun Khatun Published On 2017-05-22T12:03:21+05:30  |  Updated On 22 May 2017 12:03 PM IST

    New Delhi: Natco Pharma has received environment clearance (EC) for its Rs 480 crore expansion project in Telangana that would generate 1,500 jobs.


    The proposal is to increase the production capacity of 66 Active Pharmaceutical Ingredients (APIs) and API intermediates at a time with research and development activity from 115.5 tonnes per annum (TPA) to 645 TPA in the existing land area of 34.17 hectare at Mekaguda village in Rangareddy district.

    "The Environment Ministry has given the final environment clearance to Natco Pharma Ltd for expansion project. The approval has been given based on the recommendations of its expert committee," a senior government official said.

    The environment clearance would be subject to compliance of certain conditions, the official added.

    As per the proposal, the cost of the expansion project is estimated to be over Rs 480 crore and will provide direct employment to 1,200 and indirect jobs to 300.

    Expansion of APIs and API intermediates manufacturing facility will not only increase the market availability of therapeutic drugs but also reduce the import burden on the country, the company said.

    The Hyderabad-based company manufactures APIs in bulk quantities for both domestic and global markets. Its products are used in pharmaceutical formulation industry and manufacturing of therapeutic medicines like anti-depressant and anti-psychotic drugs, among others.

    Natco Pharma, set up in 1981, has five manufacturing facilities in India. Natco group currently has more than 3,000 employees.
    active pharmaceutical ingredientsanti-depressant drugAPIsEnvironment ClearanceNatco pharmaTelanganatherapeutic drugs
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok